"Because the industry is a typical' big money' industry, that is, high risk, long cycle and burning money, the nature of biomedicine also determines that it needs mergers and acquisitions in the current environment to become bigger and stronger."Unlike Shenzhen and Anhui, which made good use of "green channel" policies such as debt financing, mergers and acquisitions, and vigorously developed equity-based M&A funds, this time Shanghai directly gave the scale of M&A funds.The "Action Plan" proposes to strive to land a number of representative M&A cases in key industries by 2027, and cultivate about 10 internationally competitive listed companies in key industries such as integrated circuits, biomedicine and new materials.
"Because the industry is a typical' big money' industry, that is, high risk, long cycle and burning money, the nature of biomedicine also determines that it needs mergers and acquisitions in the current environment to become bigger and stronger."Bu Rixin, a partner of Chuangdao Investment Consulting, said in an interview with the science and technology innovation board Journal that the 10 billion M&A fund is mainly aimed at the "integrated circuit design industry", which may be related to the end of the IPO dividend period of chip design companies.In addition to the integrated circuit design industry, Shanghai will also set up a M&A fund for the biomedical industry with a scale of 10 billion yuan.
In its view, this 10 billion M&A fund is not only 10 billion yuan, but also a way for the government to encourage and guide M&A through the amplification of M&A funds. "In short, whether it is the M&A fund of the integrated circuit design industry or the M&A fund of biomedicine, the core purpose is to guide the orderly development of the industry and avoid the dependence on the IPO path, leading to excessive competition in the industry."Since the second half of 2024, there have been frequent large-scale acquisitions in the A-share market, and the biomedical industry has accelerated its integration. For example, China Bio-Pharmaceutical intends to acquire about 55% equity of Haooubo by means of "agreement+offer", Qianhong Pharmaceutical plans to invest 390 million yuan for bankruptcy and reorganization of Fiona Fang Pharmaceutical, Pharmacists help to acquire a piece of medicine, Xinnuowei plans to acquire 100 grams of Shiyao, and Sichuan Shuangma announced the cross-border acquisition of Jianyuan Medicine ...In addition to the integrated circuit design industry, Shanghai will also set up a M&A fund for the biomedical industry with a scale of 10 billion yuan.